Menu
Live News EQUITY M impact

Sanofi: Wayrilz Approved

Sanofi's Wayrilz is approved in Japan for immune thrombocytopenia based on the Luna 3 Phase 3 study

SNY

Sanofi’s Wayrilz Approved In Japan For Immune Thrombocytopenia: Approval Based On Luna 3 Phase 3 Study